Table 3 Hazard ratios for developing cancer in patients with CHI

Overall

2,139

1,330

2.67

(2.49–2.86)^‡

1,893

1,232

2.83

(2.63–3.05)^‡

Brain cancer

30

7

1.04

(0.45–2.39)

18

7

1.67

(0.68–4.15)

Head and neck cancer

288

66

0.96

(0.73–1.26)

171

48

1.13

(0.81–1.57)

Thyroid gland cancer

61

24

1.50

(0.93–2.42)

44

13

1.18

(0.62–2.24)

Esophageal cancer

54

15

1.42

(0.79–2.54)

46

11

1.24

(0.63–2.43)

Stomach cancer

132

32

1.11

(0.75–1.65)

122

37

1.41

(0.96–2.06)

Colorectal cancer

341

104

1.36

(1.09–1.70)^†

327

83

1.07

(0.84–1.38)

Liver cancer

155

770

1.47

(18.0–25.6)^‡

137

782

25.10

(20.9–30.2)^‡

Gallbladder and extrahepatic bile duct cancer

30

14

2.05

(1.07–3.91)*

32

18

2.60

(1.42–4.73)^†

Pancreatic cancer

35

19

2.61

(1.47–4.61)^†

55

17

1.51

(0.86–2.65)

Lung cancer

292

74

1.11

(0.86–1.44)

318

69

0.93

(0.71–1.21)

Kidney cancer

69

28

1.72

(1.10–2.68)*

68

17

0.99

(0.57–1.71)

Bladder cancer

80

24

1.24

(0.78–1.97)

87

24

1.20

(0.75–1.90)

Uterine and corpus cancer^b

43

14

1.28

(0.69–2.37)

26

11

1.82

(0.87–3.78)

Cervical cancer^b

62

10

0.74

(0.38–1.46)

62

11

0.81

(0.42–1.56)

Ovarian cancer^b

27

15

2.31

(1.21–4.39)*

10

8

5.15

(1.98–13.4)^†

Prostate cancer^c

134

30

0.95

(0.64–1.42)

136

24

0.81

(0.52–1.27)

Breast cancer^b

256

74

1.25

(0.96–1.62)

197

46

1.08

(0.78–1.50)

Melanoma

14

0

--

--

12

2

0.78

(0.17–3.60)

Skin cancer

37

15

1.46

(0.79–2.69)

37

11

1.09

(0.54–2.17)

Non-Hodgkin’s lymphoma

45

22

2.10

(1.25–3.52)^†

45

20

2.30

(1.34–3.96)^†

Myeloma

12

2

0.93

(0.20–4.25)

13

3

1.15

(0.32–4.20)

Leukemia

43

15

1.44

(0.79–2.61)

25

7

1.21

(0.51–2.87)